secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2024-04-17T23:59:59+00:00
Accession:  0001193125-24-099251
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda adopts limited-duration rights plan; rejects Future Pak's $7.25-$7.75/share bid
--------------------------------------------------------------------------------

- Board adopted a one-year stockholder rights plan effective April 17, 2024, triggered at 10% beneficial ownership.
- Plan adopted in response to unsolicited proposals from Future Pak; latest offered $7.25–$7.75 per share.
- Board unanimously rejected proposals as significantly undervaluing the company, citing robust pipeline and $6.75 cash per share.
- Rights dividend payable to shareholders of record April 29, 2024; rights expire April 16, 2025.
- Plan prevents open-market accumulation without a control premium; no shareholder action required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524099251/0001193125-24-099251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524099251/d795618d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-099251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer